{"analyses":[{"ciLowerLimit":"-120.3","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"38.2","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"40.18","groupDescription":"Weeks 9 Through 24","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.3087","paramType":"LS Mean Difference","paramValue":"-41.0","statisticalMethod":"ANCOVA"},{"ciLowerLimit":"-210.7","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"160.8","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"93.42","groupDescription":"Weeks 33 Through 48","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.7903","paramType":"LS Mean Difference","paramValue":"-24.9","statisticalMethod":"ANCOVA"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"29.25","value":"10.0"},{"groupId":"OG001","spread":"35.92","value":"51.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"128"},{"groupId":"OG001","value":"68"}],"units":"Participants"}],"title":"Weeks 9-24"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"46.13","value":"-148.8"},{"groupId":"OG001","spread":"92.19","value":"-123.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"12"}],"units":"Participants"}],"title":"Weeks 33-48"}],"denoms":[{"counts":[{"groupId":"OG000","value":"128"},{"groupId":"OG001","value":"68"}],"units":"Participants"}],"description":"Mean change from baseline in mean daily dose of ICT averaged over Week 9 to Week 24 or Week 33 to Week 48. For each participant, the mean change in daily dose of ICT was calculated as the difference of postbaseline mean daily dose and baseline mean daily dose.","dispersionType":"Standard Error","groups":[{"description":"Luspatercept 1.0 mg/Kg SC on Day 1 of each 21-day treatment cycle","id":"OG000","title":"Luspatercept"},{"description":"Placebo (Volume equivalent to experimental arm) SC on Day 1 of each 21-day treatment cycle","id":"OG001","title":"Placebo"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"All treated participants with available measurements","reportingStatus":"POSTED","timeFrame":"Baseline and Week 9 through Week 24 and Week 33 through Week 48 of study treatment","title":"Change From Baseline in Mean Daily Dose of Iron Chelation Therapy (ICT)","type":"SECONDARY","unitOfMeasure":"mg/day"}